Boehringer-Lilly launch diabetes drug Tradjenta in US
pharmafile | June 16, 2011 | News story | Sales and Marketing | Boehringer Ingelheim, Tradjenta, diabetes, lilly
Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US.
Tradjenta (linagliptin) is an oral DPP-4 inhibitor that can be used at 5mg as a monotherapy, or in combination with metformin, sulfonylurea or Takeda’s Actos, and is now available is US pharmacies.
Its purpose is to help reduce blood sugar levels in type II diabetics in combination with healthy eating and regular exercise.
The drug, which is in the same class as AstraZeneca and BMS’ Onglyza and Merck’s Januvia, is the first of its kind to be approved at one-dosage strength, even for patients who suffer from kidney or liver impairment.
This is a rapid launch for the drug, which was only approved by the FDA last month on the back of late-stage trials showing it reduces blood sugar levels by as much as 0.7% compared to placebo.
Wa’el Hashad, VP of cardiovascular and metabolic disorders at Boehringer, said: “The rapid availability of Tradjenta for adults with type II diabetes following FDA approval is a testament to Boehringer Ingelheim and Lilly’s joint commitment to improving patient care.
“The health of patients is our first priority and we work diligently to ensure our medications are accessible for patients.
“With just one dose to remember for all patients, Tradjenta is an important new treatment option that could help the millions of Americans living with type II diabetes,” he concluded.
Boehringer signed a multi-million dollar collaboration in January with Lilly to develop and commercialise a mid- to late-stage pipeline of four diabetes compounds, of which linagliptin is one.
Ben Adams
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
AOTI diabetic foot care therapy to be used by NHS
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …
